About BACCHUS. fp7.eu fp7.eu

Transcription

1 Media Kit

2 fp7.eu fp7.eu About BACCHUS BACCHUS is a four- year FP7- KBBE- funded Collaborative (Research) Project targeted at a special group (SMEs), with 27 Beneficiaries including 15 SMEs from 11 countries, led by the Institute of Food Research (IFR, UK). The main objective of the BACCHUS project is to develop tools and resources that will facilitate the generation of robust and exploitable scientific evidence that can be used to support claims of a cause and effect relationship between consumption of bioactive peptides and polyphenols, and beneficial physiological effects related to cardiovascular health in humans. To achieve this, the BACCHUS consortium has assembled 12 leading Research & Technological centres and 15 Small and Medium Enterprises (SME) (with ca 30% of the EC requested contribution allocated to the SMEs). What do we do? Our objective is to develop tools and resources that will facilitate the generation of robust and exploitable scientific evidence, which can be used to support health claims for a cause- and- effect relationship between consumption of bioactive peptides and polyphenols, and beneficial physiological effects related in cardiovascular function. Why are we doing it? Over the last few years, we have seen a rise in cardiovascular disease (CVD). Currently, this is responsible for 47% of deaths in Europe, putting pressure on international health programmes to meet targets for reducing associated risk factors, such as high blood pressure and cholesterol. Ever increasing healthcare costs, which currently total ca. 195 billion ( 157 bn), and the impact of ill health on individuals, make measures to reverse this trend are essential. Consumption of polyphenols can help reduce the risk of CVD, but pre- clinical research has also demonstrated that bioactive peptides and polyphenols can exert beneficial physiological effects on the unhealthy cardiovascular system (e.g. hypertension). This has driven further investment within the food industry, including SMEs. Despite submission of many dossiers seeking a favourable opinion from EFSA for health claims concerning polyphenols or peptides, few have been successful to date. There are specific challenges associated with proving scientifically any beneficial physiological relationship between markers for risk of CVD and consumption of bioactive peptides and polyphenols including: characterisation of the bioactive compounds, appropriate biomarkers, efficacy and dose in humans, and a plausible mechanism of action leading to a specific health claim. What is our target? Existing food products, developed by SMEs, with clear potential for a favourable health claim have been selected and aligned with research addressing key aspects of health claim evaluation (e.g. legislation and dossiers, product bioactive characterisation, intake and bioavailability, mechanisms of action and biomarkers, randomised controlled trials). This approach will deliver tools, processes, scientific results and best practice guidelines, which will be made publically available to support future health claims. BACCHUS outcomes will be disseminated broadly within the SME food and retail community as well as traditional scientific routes. Beneficial Effects of Bioactive Compounds in Humans (BACCHUS) Grant Agreement No:

3 fp7.eu fp7.eu One of the main outcomes of BACCHUS will be improved products/ ingredient including: Ellagitannin- rich pomegranate (ADMIRA) Polyphenol- enriched apple products (CORRESSENCE) Catechin- and flavonol glycoside- rich apple extracts (VITO) Polyphenol- enriched chokeberry juice (NUTRIEKA) Hesperion sweet orange extract (BIOACTOR) Novel ellagitannin- rich varieties and products (Lerum) Bioactive peptide- enriched meats and meat products (VAQUERO & VALDYCOMER) Tensiocontrol (BIOACTOR) Lunasin- rich wheat pasta and breads (KEE & BIOAESIS) Who are we? For more information about BACCHUS participants visit fp7.eu/bacchus- participants Beneficial Effects of Bioactive Compounds in Humans (BACCHUS) Grant Agreement No:

4 fp7.eu fp7.eu Key aspects of EFSA Health Claims addressed by BACCHUS:: - Legislation and dossiers - Bioactive characterisation - Habitual intakes Bioavailability - Mechanisms of action and biomarkers - Evidence of health benefit in appropriate population group(s) Expected outcomes: - Best practice guidelines for supporting future health claims - Wider scope for existing bioactive database (ebasis) - Targeted training Beneficial Effects of Bioactive Compounds in Humans (BACCHUS) Grant Agreement No:

5 fp7.eu fp7.eu Key people in BACCHUS Paul Kroon Position: Project Coordinator Institution: Institute of Food Research, Norwich, UK E- mail: Paul Finglas Position: Project Co- coordinator Institution: Institute of Food Research, Norwich, UK E- mail: Dawn Wright Position: Project Manager Institution: Institute of Food Research, Norwich, UK E- mail: François Heroufosse Position: Project Training Manager Institution: WagrAlim, Belgium E- mail: Norbert Bomba Position: Project Dissemination Leader Institution: PAMIDA International, Slovakia E- mail: Beneficial Effects of Bioactive Compounds in Humans (BACCHUS) Grant Agreement No:

6 fp7.eu fp7.eu Media contacts Andrew Chapple press officer Norwich, United Kingdom (native speaker): Telephone: +44 (0) Mobile: +44 (0) E- mail: Matej Pavlik communication manager - Bratislava, Slovak republic Mobile: E- mail: [email protected] Social media profiles LinkedIn: Twitter: Slideshare: BACCHUS is a Collaborative (Research) Project targeted at a special group (SMEs) under the European Commission 7th Framework Programme, Specific Programme 'Cooperation' - Research Theme: 'Food, agriculture and fisheries, and biotechnology' within the FP7- KBBE single- stage, under Grant Agreement no Beneficial Effects of Bioactive Compounds in Humans (BACCHUS) Grant Agreement No: